1921
Volume 94, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Globally, scabies affects more than 130 million people at any time. In the developed world, outbreaks in health institutions and vulnerable communities result in a significant economic burden. A review of the literature demonstrates the emergence of resistance toward classical scabicidal treatments and the lack of effectiveness of currently available scabicides in reducing the inflammatory skin reactions and pyodermal progression that occurs in predisposed patient cohorts. Tea tree oil (TTO) has demonstrated promising acaricidal effects against scabies mites in vitro and has also been successfully used as an adjuvant topical medication for the treatment of crusted scabies, including cases that did not respond to standard treatments. Emerging acaricide resistance threatens the future usefulness of currently used gold standard treatments (oral ivermectin and topical permethrin) for scabies. The imminent development of new chemical entities is doubtful. The cumulative acaricidal, antibacterial, antipruritic, anti-inflammatory, and wound healing effects of TTO may have the potential to successfully reduce the burden of scabies infection and the associated bacterial complications. This review summarizes current knowledge on the use of TTO for the treatment of scabies. On the strength of existing data for TTO, larger scale, randomized controlled clinical trials are warranted.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.14-0515
2016-02-03
2017-11-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/94/2/258.html?itemId=/content/journals/10.4269/ajtmh.14-0515&mimeType=html&fmt=ahah

References

  1. Walton SF, McKinnon M, Pizzutto S, Dougall A, Williams E, Currie BJ, , 2004. Acaricidal activity of Melaleuca alternifolia (tea tree) oil: in vitro sensitivity of Sarcoptes scabiei var hominis to terpinen-4-ol. Arch Dermatol 140: 563566.[Crossref]
  2. Hicks MI, Elston DM, , 2009. Scabies. Dermatol Ther 22: 279292.[Crossref]
  3. Engelman D, Kiang K, Chosidow O, McCarthy J, Fuller C, Lammie P, Hay R, Steer A, Members Of The International Alliance For The Control Of Scabies; , 2013. Toward the global control of human scabies: introducing the international alliance for the control of scabies. PLoS Negl Trop Dis 7: e2167.[Crossref]
  4. World Health Organization, 2005. Epidemiology and Management of Common Skin Diseases in Children in Developing Countries. Geneva, Switzerland: WHO. Available at: http://whqlibdoc.who.int/hq/2005/WHO_FCH_CAH_05.12_eng.pdf?ua. Accessed January 20, 2014.
  5. Andrews RM, Kearns T, Connors C, Parker C, Carville K, Currie BJ, Carapetis JR, , 2009. A regional initiative to reduce skin infections amongst aboriginal children living in remote communities of the Northern Territory, Australia. PLoS Negl Trop Dis 3: e554.[Crossref]
  6. Heukelbach J, Mazigo HD, Ugbomoiko US, , 2013. Impact of scabies in resource-poor communities. Curr Opin Infect Dis 26: 127132.[Crossref]
  7. Mounsey KE, McCarthy JS, Walton SF, , 2013. Scratching the itch: new tools to advance understanding of scabies. Trends Parasitol 29: 3542.[Crossref]
  8. Chosidow O, , 2006. Clinical practices. Scabies. N Engl J Med 354: 17181727.[Crossref]
  9. McCarthy JS, Kemp DJ, Walton SF, Currie BJ, , 2004. Scabies: more than just an irritation. Postgrad Med J 80: 382387.[Crossref]
  10. Walton SF, Holt DC, Currie BJ, Kemp DJ, , 2004. Scabies: new future for a neglected disease. Adv Parasitol 57: 309376.[Crossref]
  11. Hay RJ, , 2009. Scabies and pyodermas-diagnosis and treatment. Dermatol Ther (Heidelb) 22: 466474.[Crossref]
  12. Hengge UR, Currie BJ, Jager G, Lupi O, Schwartz RA, , 2006. Scabies: a ubiquitous neglected skin disease. Lancet Infect Dis 6: 769779.[Crossref]
  13. Mika A, Reynolds SL, Pickering D, McMillan D, Sriprakash KS, Kemp DJ, Fischer K, , 2012. Complement inhibitors from scabies mites promote streptococcal growth—a novel mechanism in infected epidermis? PLoS Negl Trop Dis 6: e1563.[Crossref]
  14. Bergström FC, Reynolds S, Johnstone M, , 2009. Scabies mite inactivated serine protease paralogs inhibit the human complement system. J Immunol 182: 78097817.[Crossref]
  15. Mika A, Reynolds SL, Mohlin FC, , 2012. Novel scabies mite serpins inhibit the three pathways of the human complement system. PLoS One 7: e40489.[Crossref]
  16. Swe PM, Reynolds SL, Fischer K, , 2014. Parasitic scabies mites and associated bacteria joining forces against host complement defence. Parasite Immunol 36: 583591.[Crossref]
  17. Carapetis J, Walker A, Hibble M, Sriprakash K, Currie B, , 1999. Clinical and epidemiological features of group A streptococcal bacteraemia in a region with hyperendemic superficial streptococcal infection. Epidemiol Infect 122: 5965.[Crossref]
  18. Vos T, Barker B, Begg S, Stanley L, Lopez AD, , 2009. Burden of disease and injury in Aboriginal and Torres Strait Islander Peoples: the Indigenous health gap. Int J Epidemiol 38: 470477.[Crossref]
  19. Andrews RM, McCarthy J, Carapetis JR, Currie BJ, , 2009. Skin disorders, including pyoderma, scabies, and tinea infections. Pediatr Clin North Am 56: 14211440.[Crossref]
  20. Owusu-Edusei K, Jr. Chesson HW, Gift TL, , 2009. The economic burden of pediculosis pubis and scabies infections treated on an outpatient basis in the United States: evidence from private insurance claims data, 2001–2005. Sex Transm Dis 36: 297299.[Crossref]
  21. Kearns T, Clucas D, Connors C, Currie BJ, Carapetis JR, Andrews RM, , 2013. Clinic attendances during the first 12 months of life for Aboriginal children in five remote communities of northern Australia. PloS One 8: e58231.[Crossref]
  22. Whitehall J, Kuzulugil D, Sheldrick K, Wood A, , 2013. Burden of paediatric pyoderma and scabies in North West Queensland. J Paediatr Child Health 49: 141143.[Crossref]
  23. Strong M, Johnstone P, , 2007. Interventions for treating scabies. Cochrane Database Syst Rev 18: CD000320.
  24. Currie BJ, McCarthy JS, , 2010. Permethrin and ivermectin for scabies. N Engl J Med 362: 717725.[Crossref]
  25. Walker GJA, Johnstone PW, , 2000. Interventions for treating scabies. Cochrane Database Syst Rev 3: CD000320.
  26. Kemp DJ, Walton SF, Harumal P, Currie BJ, , 2002. The scourge of scabies. Biologist 49: 1924.
  27. Goldust M, Rezaee E, Hemayat S, , 2012. Treatment of scabies: comparison of permethrin 5% versus ivermectin. J Dermatol 39: 545547.[Crossref]
  28. Haas N, Lindemann U, Frank K, Sterry W, Lademann J, Katzung W, , 2002. Rapid and preferential sebum secretion of ivermectin: a new factor that may determine drug responsiveness in patients with scabies. Arch of Dermatol 138: 16181619.[Crossref]
  29. Pasay C, Walton S, Fischer K, Holt D, McCarthy J, , 2006. PCR-based assay to survey for knockdown resistance to pyrethroid acaricides in human scabies mites (Sarcoptes scabiei var hominis). Am J Trop Med Hyg 74: 649657.
  30. Leibowitz M, , 1993. Failure of scabies treatment. New Zeal Med J 106: 317.
  31. Pasay C, Arlian L, Morgan M, , 2008. High-resolution melt analysis for the detection of a mutation associated with permethrin resistance in a population of scabies mites. Med Vet Entomol 22: 8288.[Crossref]
  32. Mounsey KE, Holt DC, McCarthy JS, Currie BJ, Walton SF, , 2009. Longitudinal evidence of increasing in vitro tolerance of scabies mites to ivermectin in scabies-endemic communities. Arch Dermatol 145: 840841.[Crossref]
  33. Rizvi SDA, Iftikhar N, Batool F, , 2011. Effectiveness of oral ivermectin for eradicating infesting mites in patients of scabies. J Pak Assoc Derma 21: 8792.
  34. Van den Hoek J, Van de Weerd J, Baayen T, , 2008. A persistent problem with scabies in and outside a nursing home in Amsterdam: indications for resistance to lindane and ivermectin. Euro Surveill 13: 514.
  35. Currie BJ, Connors CM, Krause VL, , 1994. Scabies programs in aboriginal communities. Med J Aust 161: 636637.
  36. Andriantsoanirina V, Izri A, Botterel F, Foulet F, Chosidow O, Durand R, , 2014. Molecular survey of knockdown resistance to pyrethroids in human scabies mites. Clin Microbiol Infec 20: O139O141.[Crossref]
  37. Mounsey KE, Holt DC, McCarthy J, Currie BJ, Walton SF, , 2008. Scabies: molecular perspectives and therapeutic implications in the face of emerging drug resistance. Future Microbiol 3: 5766.[Crossref]
  38. Ly F, Caumes E, Ndaw CA, Ndiaye B, Mahe A, , 2009. Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in Dakar, Senegal: a randomized controlled trial. Bull World Health Organ 87: 424430.[Crossref]
  39. Walton SF, Beroukas D, Roberts-Thomson P, Currie BJ, , 2008. New insights into disease pathogenesis in crusted (Norwegian) scabies: the skin immune response in crusted scabies. Brit J Dermatol 158: 12471255.[Crossref]
  40. Bouvresse S, Chosidow O, , 2010. Scabies in healthcare settings. Curr Opin Infect Dis 23: 111118.[Crossref]
  41. Reuter J, Merfort I, Schempp CM, , 2010. Botanicals in dermatology. Am J Clin Dermatol 11: 247267.
  42. Tabassum N, Hamdani M, , 2014. Plants used to treat skin diseases. Pharmacogn Rev 8: 5260 [Crossref]
  43. Sharma J, Gairola S, Sharma YP, Gaur R, , 2014. Ethnomedicinal plants used to treat skin diseases by Tharu community of district Udham Singh Nagar, Uttarakhand, India. J Ethnopharmacol 158: 140206.[Crossref]
  44. Carson C, Hammer K, Riley T, , 2006. Melaleuca alternifolia (tea tree) oil: a review of antimicrobial and other medicinal properties. Clin Microbiol Rev 19: 5062.[Crossref]
  45. Joksimovic N, Spasovski G, Joksimovic V, Andreevski V, Zuccari C, Omini C, , 2012. Efficacy and tolerability of hyaluronic acid, tea tree oil and methyl-sulfonyl-methane in a new gel medical device for treatment of haemorrhoids in a double-blind, placebo-controlled clinical trial. Surgery 64: 195201.
  46. Papadopoulos CJ, Carson CF, Hammer KA, Riley TV, , 2006. Susceptibility of pseudomonads to Melaleuca alternifolia (tea tree) oil and components. Journal Antimicrob Chemother 58: 449451.[Crossref]
  47. Brand C, Ferrante A, Prager RH, , 2001. The water-soluble components of the essential oil of Melaleuca alternifolia (tea tree oil) suppress the production of superoxide by human monocytes, but not neutrophils, activated in vitro. Inflamm Res 50: 213239.[Crossref]
  48. Koh K, Pearce A, Marshman G, Finlay-Jones J, Hart P, , 2002. Tea tree oil reduces histamine-induced skin inflammation. Brit J Dermatol 147: 12121217.[Crossref]
  49. Williamson EM, , 2007. The medicinal use of essential oils and their components for treating lice and mite infestations. Nat Prod Commun 2: 13031310.
  50. Wallengren J, , 2011. Tea tree oil attenuates experimental contact dermatitis. Arch Dermatol Res 303: 333338.[Crossref]
  51. Fitzi J, Fürst-Jucker J, Wegener T, Saller R, Reichling J, , 2002. Phytotherapy of chronic dermatitis and pruritus of dogs with a topical preparation containing tea tree oil (Bogaskin®). Schweiz Arch Tierheilkd 144: 223231.[Crossref]
  52. Reichling J, Fitzi J, Hellmann K, Wegener T, Bucher S, Saller R, , 2004. Topical tea tree oil effective in canine localised pruritic dermatitis-a multi-centre randomised double-blind controlled clinical trial in the veterinary practice. Dtsch Tierarztl Wochenschr 111: 408414.
  53. Choi W-I, Lee E-H, Choi B-R, Park H-M, Ahn Y-J, , 2003. Toxicity of plant essential oils to Trialeurodes vaporariorum (Homoptera: Aleyrodidae). J Econ Entomol 96: 14791484.[Crossref]
  54. Barker SC, Altman PM, , 2010. A randomised, assessor blind, parallel group comparative efficacy trial of three products for the treatment of head lice in children-melaleuca oil and lavender oil, pyrethrins and piperonyl butoxide, and a “suffocation” product. BMC Dermatol 10: 6.[Crossref]
  55. James P, Callander J, , 2012. Bioactivity of tea tree oil from Melaleuca alternifolia against sheep lice (Bovicola ovis Schrank) in vitro. Vet Parasitol 187: 498504.[Crossref]
  56. Williamson E, Priestley C, Burgess I, , 2007. An investigation and comparison of the bioactivity of selected essential oils on human lice and house dust mites. Fitoterapia 78: 521525.[Crossref]
  57. Gao Y, Di Pascuale M, Li W, , 2005. In vitro and in vivo killing of ocular Demodex by tea tree oil. Br J Ophthalmol 89: 14681473.[Crossref]
  58. Gao Y-Y, Di Pascuale MA, Elizondo A, Tseng SC, , 2007. Clinical treatment of ocular demodecosis by lid scrub with tea tree oil. Cornea 26: 136143.[Crossref]
  59. Mägi E, Järvis T, Miller I, , 2006. Effects of different plant products against pig mange mites. Acta Vet Brno 75: 283287.[Crossref]
  60. Walton S, Myerscough M, Currie B, , 2000. Studies in vitro on the relative efficacy of current acaricides for Sarcoptes scabiei var. hominis. Trans R Soc Trop Med Hyg 94: 9296.[Crossref]
  61. Walton SF, McKinnon M, Pizzutto S, Dougall A, Williams E, Currie BJ, , 2004. Acaricidal activity of Melaleuca alternifolia (tea tree) oil: in vitro sensitivity of sarcoptes scabiei var hominis to terpinen-4-ol. Arch Dermatol 140: 563.[Crossref]
  62. Davis JS, McGloughlin S, Tong SY, Walton SF, Currie BJ, , 2013. A Novel Clinical Grading Scale to Guide the Management of Crusted Scabies. PLoS Negl Trop Dis 7: e2387.[Crossref]
  63. Greig JE, , 1999. Skin sensitivity testing for tea tree oil: RIRDC project UWA-42A, RIRDC Publication R99/076: 5460.
  64. Rutherford T, Nixon R, Tam M, Tate B, , 2006. Tea tree oil: an increasing common but underreported allergen—our experience at the Skin and Cancer Foundation, Melbourne from 1999 to 2004, Abstract presented at the 39th Annual Scientific Meeting 14–17 May 2006 Melbourne, Victoria. Australasian Journal of Dermatology 47: A1A54.[Crossref]
  65. Veien NK, Rosner K, Skovgaard GL, , 2004. Is tea tree oil an important contact allergen? Contact dermatitis 50: 378379.[Crossref]
  66. Baillie J, , 2012. Combination of Essential Oil of Melaleuca altemifolia and Iodine in the Treatment of Molluscum Contagiosum in Children. J Drugs Dermatol 11: 349354.
  67. Aspres N, Freeman S, , 2004. Predictive testing for irritancy and allergenicity of tea tree oil in normal human subjects. Exog Dermatol 2: 258261.[Crossref]
  68. Hausen BM, Reichling J, Harkenthal M, , 1999. Degradation products of monoterpenes are the sensitizing agents in tea tree oil. Am J Contact Dermat 10: 6877.[Crossref]
  69. Brophy JJ, Davies NW, Southwell IA, Stiff IA, Williams LR, , 1989. Gas chromatographic quality control for oi l of Melaleuca terpinen-4-ol type (Australian tea tree). J Agric Food Chem 37: 13301335.[Crossref]
  70. Hammer K, Carson C, Riley T, , 2003. Antifungal activity of the components of Melaleuca alternifolia (tea tree) oil. J Appl Microbio 95: 853860.[Crossref]
  71. Cross SE, Russell M, Southwell I, Roberts MS, , 2008. Human skin penetration of the major components of Australian tea tree oil applied in its pure form and as a 20% solution in vitro. Eur J Pharm Biopharm 69: 214222.[Crossref]
  72. Carson C, Riley T, , 1995. Antimicrobial activity of the major components of the essential oil of Melaleuca alternifolia. J Appl Bacteriol 78: 264269.[Crossref]
  73. Hammer KA, Carson CF, Riley TV, Nielsen JB, , 2006. A review of the toxicity of Melaleuca alternifolia (tea tree) oil. Food Chem Toxicol 44: 616625.[Crossref]
  74. The International Alliance for the Control of Scabies, 2014. Scabies added to the World Health Organisation list of Neglected Tropical Diseases. Available at: http://www.controlscabies.org/news/scabies-added-list-who-ntds/. Accessed January 14, 2014.
  75. Sherry E, Sivananthan S, Warnke PH, Eslick GD, , 2003. Topical phytochemicals used to salvage the gangrenous lower limbs of type 1 diabetic patients. Diabetes Res Clin Pract 62: 6566.[Crossref]
  76. Hartman D, Coetzee J, , 2002. Two US practitioners' experience of using essential oils for wound care. Wound Care 11: 317320.[Crossref]
  77. Roin BN, , 2008. Unpatentable drugs and the standards of patentability. Tex L Rev 87: 503.
  78. Clucas DB, Carville KS, Connors C, Currie BJ, Carapetis JR, Andrews RM, , 2008. Disease burden and health-care clinic attendances for young children in remote Aboriginal communities of northern Australia. Bull World Health Organ 86: 275281.[Crossref]
  79. Blackwood B, Thompson G, McMullan R, , 2013. Tea tree oil (5%) body wash versus standard care (Johnson's Baby Softwash) to prevent colonization with methicillin-resistant Staphylococcus aureus in critically ill adults: a randomized controlled trial. J Antimicrob Chemother 68: 11931199.[Crossref]
  80. Sule HM, Thacher TD, , 2007. Comparison of ivermectin and benzyl benzoate lotion for scabies in Nigerian patients. Am J Trop Med Hyg 76: 392395.
  81. Coleman CI, Gillespie EL, White CM, , 2005. Probable topical permethrin-induced neck dystonia. Pharmacotherapy 25: 448450.[Crossref]
  82. Goldust M, Rezaee E, Raghifar R, Hemayat S, , 2013. Treatment of scabies: the topical ivermectin vs. permethrin 2.5% cream. Ann Parasitol 59: 7984.
  83. Sharquie KE, Al-Rawi JR, Noaimi AA, Al-Hassany HM, , 2012. Treatment of scabies using 8% and 10% topical sulfur ointment in different regimens of application. J Drugs Dermatol 11: 357364.
  84. Ito T, , 2013. Mazzotti reaction with eosinophilia after undergoing oral ivermectin for scabies. J Dermatol 40: 776777.[Crossref]
  85. Barkwell R, Shields S, , 1997. Deaths associated with ivermectin treatment of scabies. Lancet 349: 11441145.[Crossref]
  86. Chouela EN, Abeldano AM, Pellerano G, , 1999. Equivalent therapeutic efficacy and safety of ivermectin and lindane in the treatment of human scabies. Arch Dermatol 135: 651655.[Crossref]
  87. Brooks P, Grace R, , 2002. Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. J Paediatr Child Health 38: 401414.[Crossref]
  88. Glaziou P, Cartel J, Alzieu P, Briot C, Moulia-Pelat J, Martin P, , 1993. Comparison of ivermectin and benzyl benzoate for treatment of scabies. Trop Med Parasitol 44: 331332.
  89. Nnoruka E, Agu C, , 2001. Successful treatment of scabies with oral ivermectin in Nigeria. Trop Doct 31: 1518.[Crossref]
  90. Schultz MW, Gomez M, Hansen RC, , 1990. Comparative study of 5% permethrin cream and 1% lindane lotion for the treatment of scabies. Arch of Dermatol 126: 167170.[Crossref]
  91. Strong M, Johnstone P, , 2007. Interventions for treating scabies. Cochrane Database Syst Rev 3: 159.
  92. Fujimoto K, Kawasaki Y, Morimoto K, Kikuchi I, Kawana S, , 2014. Treatment for crusted scabies: limitations and side effects of treatment with ivermectin. Nippon Med Sch 81: 157163.[Crossref]
  93. Fujimoto K, , 2014. Mucosal drug eruption in an elderly patient: case report. Reactions 1510: 2729.
  94. Burkhart CG, , 1983. Scabies: an epidemiologic reassessment. Ann Intern Med 98: 498503.[Crossref]
  95. Burkhart CG, Burkhart CN, Burkhart KM, , 2000. An epidemiologic and therapeutic reassessment of scabies. Cutis 65: 233242.
  96. Bouvresse S, Chosidow O, , 2010. Scabies in healthcare settings. Curr Opin Infect Dis 23: 111118.[Crossref]
  97. Roos TC, Roos S, Merk HF, Bickers DR, , 2001. Pharmacotherapy of ectoparasitic infections. Drugs 61: 10671088.[Crossref]
  98. Heukelbach J, Winter B, Wilcke T, , 2004. Selective mass treatment with ivermectin to control intestinal helminthiases and parasitic skin diseases in a severely affected population. Bull World Health Organ 82: 563571.
  99. Hay R, Steer A, Engelman D, Walton S, , 2012. Scabies in the developing world—its prevalence, complications, and management. Clin Microbiol Infec 18: 313332.[Crossref]
  100. The International Alliance for the Control of Scabies, 2014. Scabies Added to the World Health Organization List of Neglected Tropical Diseases. Available at: http://www.controlscabies.org/news/scabies-added-list-who-ntds/. Accessed January 14, 2014.
  101. Sherry E, Sivananthan S, Warnke PH, Eslick GD, , 2003. Topical phytochemicals used to salvage the gangrenous lower limbs of type 1 diabetic patients. Diabetes Res Clin Pract 62: 6566.[Crossref]
  102. Hartman D, Coetzee J, , 2002. Two US practitioners' experience of using essential oils for wound care. Wound Care 11: 317320.[Crossref]
  103. Roin BN, , 2008. Unpatentable drugs and the standards of patentability. Tex Law Rev 87: 503.
  104. Clucas DB, Carville KS, Connors C, Currie BJ, Carapetis JR, Andrews RM, , 2008. Disease burden and health-care clinic attendances for young children in remote Aboriginal communities of northern Australia. Bull World Health Organ 86: 275281.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.14-0515
Loading
/content/journals/10.4269/ajtmh.14-0515
Loading

Data & Media loading...

  • Received : 12 Aug 2014
  • Accepted : 08 May 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error